On the safety of intravenous iron, evidence trumps conjecture

Haematologica

Volumn 100, Issue 5, 2015, Pages E214-E215

  Auerbach, Michael ^a   Adamson, John ^b   Bircher, Andreas ^c   Breymann, Christian ^d   Fishbane, Steven ^e   Gafter Gvili, Anat ^f   Gasche, Christoph ^g   Gilreath, Jeffrey ^h   Grazzini, Giuliano ⁱ   Henry, David ^j   Liumbruno, Giancarlo ⁱ   Locatelli, Francesco ^k   Macdougall, Iain ^l   Munoz, Manuel ^m   Rampton, David ⁿ   Rodgers, George ^o   Shander, Aryeh ^p  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^f RABIN MEDICAL CENTER   (Israel)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁱ ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k A MANZONI HOSPITAL   (Italy)

^l KING'S COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY OF MÁLAGA   (Spain)

ⁿ QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^o UNIVERSITY OF UTAH   (United States)

^p MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Current; Efficacy; Evidence; Intravenous iron formulations; Safety; Studies

Indexed keywords

DIPHENHYDRAMINE; FERRIC CARBOXYMALTOSE; FERUMOXYTOL; IRON; IRON DEXTRAN; IRON SACCHARATE;

ANEMIA; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT; INTRAVENOUS DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ANEMIA; HUMANS; IRON;

EID: 84929173088     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.121004     Document Type: Letter

References (16)

1. Kassebaum N, Jasasaria R, Naghavi N, et al. A systemic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123(5):615-624.
2. Chertow G, Mason P, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21(2):378-382.
3. Wysowski D, Swartz L, Borders-Hemphill V, et al. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010;85(9):650-654.
4. European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. 28 June 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144874.pdf
5. Prescrire International Translated from Rev Prescrire. 2014; 34(365):182-183.
6. Critchley J, Dundar Y. Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review. Transfus Alternat Transfus Med. 2007;9(1):8-36.
7. Okam M, Mandell E, Hevelone N, et al. Comparative rates of adverse events with different formulations of intravenous iron. Am J Hematol. 2012;87:E123-E124.
8. Rodgers G, Auerbach M, Cell D, et al. High-molecular weight iron dextran: a wolf in sheep’s clothing? J Am Soc Nephrol. 2008;19(5):833-834.
9. Myers B, Myers O, Moore J. Comparative efficacy and safety of intravenous ferric carboxymaltose (Ferinject) and iron(III) hydroxide dextran (Cosmofer) in pregnancy. Obstet Med. 2012;5(3):105-107.
10. Auerbach M, Pappadakis J, Bahrain H, et al. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol. 2011;86(10):860-862.
11. Macdougall I, Strauss W, McLaughlin J, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol. 2014;9(4):705-712.
12. Hussain I, Bhoyroo J, Butcher A, et al. Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia. Anemia. 2013 Aug 29. [Epub ahead of print]
13. Avni T, Bierber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clinic Proc. 2015;90(1):12-23.
14. Barton J, Barton E, Bertoli L, et al. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med. 2000;109(1):27-32.
15. Fishbane S, Ungureanu V, Maesaka J, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996;28(4):529-534.
16. Bircher A, Auerbach M. Hypersensitivity from intravenous iron products. Immunol Allergy Clin N Am. 2014;34(3):707-723.